CA
NZ
UK
AU
IND
US
…
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company provides its precision oncology solutions to customers, such as hospitals, institutions and patients. The company was founded in 2008 and is headquartered in Irving, Texas.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Caris Life Sciences provides molecular profiling and precision oncology diagnostic services that analyze tumor biology to inform treatment selection and clinical trial matching. Long-term growth drivers include broader adoption of precision medicine, rising demand for comprehensive genomic and biomarker testing, and the value of real-world molecular data to support drug development, which could support revenue diversification. Investors may find the company attractive for its integrated testing capabilities and data assets positioned at the intersection of diagnostics and targeted therapies.
Material risks include reimbursement uncertainty and regulatory changes, intense competition from other diagnostic and sequencing providers, and execution challenges scaling operations while safeguarding patient data.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2020-12-31 |
| Income before tax | -68.09M | -281.89M | -341.42M | -320.83M | 29.53M |
| Net income | -537.96M | -281.89M | -341.42M | -320.83M | 27.73M |
| Selling general administrative | 224.97M | 173.56M | 151.95M | 156.15M | 27.31M |
| Selling and marketing expenses | 167.51M | 148.30M | 139.53M | 138.36M | - |
| Gross profit | 539.17M | 178.78M | 89.31M | 80.02M | 184.16M |
| Reconciled depreciation | 22.61M | 48.91M | 49.00M | 48.25M | - |
| Ebit | -11.23M | -231.87M | -309.81M | -294.15M | 143.81M |
| Ebitda | 11.38M | -182.95M | -260.80M | -245.89M | 254.46M |
| Depreciation and amortization | 22.61M | 48.91M | 49.00M | 48.25M | 110.65M |
| Operating income | 45.11M | -257.12M | -319.55M | -315.76M | 139.09M |
| Other operating expenses | 766.92M | 669.38M | 625.68M | 574.24M | 154.93M |
| Interest expense | 56.85M | 50.02M | 31.61M | 26.68M | 61.56M |
| Tax provision | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Interest income | 16.50M | 7.12M | 11.26M | 0.95M | - |
| Net interest income | -40.36M | -42.90M | -20.35M | -25.73M | - |
| Income tax expense | 469.87M | - | - | - | 1.80M |
| Total revenue | 812.03M | 412.26M | 306.13M | 258.49M | 294.01M |
| Total operating expenses | 494.06M | 435.90M | 408.86M | 395.78M | 45.07M |
| Cost of revenue | 272.87M | 233.48M | 216.82M | 178.46M | 109.86M |
| Total other income expense net | -113.20M | -24.77M | -21.86M | -5.07M | -109.55M |
| Net income from continuing ops | -68.09M | -281.89M | -341.42M | -320.83M | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2020-12-31 |
| Total assets | 1125.66M | 343.73M | 412.90M | 717.42M | 2612.63M |
| Other current assets | 85.57M | 21.76M | 16.73M | 19.24M | -62.18M |
| Total liab | 548.36M | 2842.57M | 2557.85M | 2419.53M | 1910.39M |
| Total stockholder equity | 577.31M | -2498.84M | -2144.95M | -1702.11M | 702.24M |
| Other current liab | 87.77M | 63.99M | 56.03M | 51.11M | 130.11M |
| Common stock | 0.28M | 0.04M | 0.04M | 0.14M | 0.00M |
| Capital stock | 0.28M | 0.04M | 0.04M | 0.14M | - |
| Retained earnings | -2548.74M | -2472.30M | -2119.18M | -1678.65M | 503.32M |
| Good will | 19.34M | 19.34M | 19.34M | 19.34M | - |
| Cash | 797.80M | 63.95M | 56.40M | 107.19M | 53.55M |
| Total current liabilities | 127.14M | 165.42M | 95.14M | 136.91M | 320.25M |
| Current deferred revenue | - | 7.47M | 5.68M | 1.43M | 3.03M |
| Net debt | -418.81M | 360.31M | 160.87M | 163.68M | 1692.18M |
| Short term debt | 0.17M | 66.17M | 6.75M | 57.09M | 183.45M |
| Short long term debt | - | 60.00M | 0.17M | 52.79M | - |
| Short long term debt total | 378.99M | 424.26M | 217.27M | 270.87M | 1745.73M |
| Other stockholder equity | 3124.82M | -26.79M | -26.03M | -25.30M | 100.80M |
| Total current assets | 997.80M | 215.73M | 242.61M | 516.04M | 214.66M |
| Short term investments | 2.29M | 2.20M | 65.18M | 302.43M | 78.99M |
| Net receivables | 112.14M | 88.24M | 55.30M | 40.23M | 144.30M |
| Long term debt | 378.45M | 319.19M | 166.11M | 169.57M | - |
| Inventory | 63.62M | 39.57M | 49.00M | 46.96M | - |
| Accounts payable | 39.21M | 27.79M | 26.68M | 27.27M | 3.67M |
| Accumulated other comprehensive income | 0.94M | 0.21M | 0.22M | 1.70M | -5.74M |
| Non currrent assets other | 45.35M | 5.89M | 3.43M | 43.98M | 616.65M |
| Non current assets total | 127.86M | 128.00M | 170.29M | 201.38M | 2397.97M |
| Capital lease obligations | 49.24M | 45.06M | 51.00M | 48.51M | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2020-12-31 |
| Investments | 0.00M | 52.93M | 214.77M | -282.99M | - |
| Total cashflows from investing activities | -16.26M | 52.93M | 214.77M | -282.99M | -33.97M |
| Net borrowings | 27.76M | 199.82M | 10.57M | -0.96M | - |
| Total cash from financing activities | 664.99M | 200.29M | 10.13M | 10.45M | -249.88M |
| Net income | -68.09M | -281.89M | -341.42M | -320.83M | 27.73M |
| Change in cash | 732.01M | 8.02M | -51.13M | -558.25M | -6.74M |
| Begin period cash flow | 68.03M | 60.01M | 111.14M | 669.38M | 73.24M |
| End period cash flow | 800.04M | 68.03M | 60.01M | 111.14M | 66.50M |
| Total cash from operating activities | 83.16M | -245.20M | -276.10M | -285.71M | 277.02M |
| Issuance of capital stock | 649.70M | 0.00M | 0.00M | - | - |
| Depreciation | 22.61M | 48.91M | 49.00M | 48.25M | 110.65M |
| Other cashflows from investing activities | - | - | - | - | 185.48M |
| Dividends paid | - | - | - | - | 17.71M |
| Change to inventory | -20.75M | 5.46M | -4.43M | -11.10M | - |
| Change to account receivables | -29.79M | -33.82M | -15.08M | -11.90M | 11.00M |
| Sale purchase of stock | -0.11M | 0.00M | 0.00M | - | -7.95M |
| Other cashflows from financing activities | -18.55M | 0.47M | -0.43M | 11.41M | -232.18M |
| Capital expenditures | 16.26M | 8.44M | 22.32M | 42.26M | 219.45M |
| Change in working capital | -33.13M | -29.07M | -7.13M | -22.26M | -317.31M |
| Stock based compensation | 70.01M | 18.64M | 15.24M | 22.90M | 1.77M |
| Other non cash items | 91.75M | -1.80M | 8.20M | -13.78M | 452.80M |
| Free cash flow | 66.89M | -253.64M | -298.42M | -327.96M | 57.57M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CAI Caris Life Sciences, Inc. Common Stock |
-1.81 5.01% |
34.33 | - | 39.37 | 7.25 | 10.20 | 6.79 | 484.64 |
| NVO Novo Nordisk A/S |
0.86 2.20% |
40.00 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
18.88 3.50% |
558.88 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
109.12 13.33% |
927.89 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company provides its precision oncology solutions to customers, such as hospitals, institutions and patients. The company was founded in 2008 and is headquartered in Irving, Texas.
750 West John Carpenter Freeway, Irving, TX, United States, 75039
866 771 8946
1846
| Name | Title | Year Born |
|---|---|---|
| Dr. David Dean Halbert M.D. | Chairman, CEO & Founder | 1956 |
| Mr. Brian J. Brille J.D. | Executive Vice Chairman & Executive VP | 1962 |
| Dr. David Spetzler M.B.A., M.S., Ph.D. | President | 1977 |
| Mr. Luke Power | Senior VP, CFO & Chief Accounting Officer | 1982 |
| Mr. Jon Mark Harmon | Senior VP & Chief Operations Officer | NA |
| Dr. Valeriy Domenyuk | Senior VP & CTO | NA |
| Dr. Milan Radovich Ph.D. | Senior VP & Chief Scientific Officer | NA |
| Ms. Ginger Appleberry J.D. | Senior VP, Deputy General Counsel & Chief Compliance Officer | NA |
| Mr. J. Russel Denton | Senior VP, General Counsel & Secretary | 1984 |
| Mr. Narendra Chokshi | Senior Vice President of Corporate Development | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...